These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10022409)

  • 1. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction.
    Lafage-Proust MH; Combe C; Barthe N; Aparicio M
    J Clin Endocrinol Metab; 1999 Feb; 84(2):512-9. PubMed ID: 10022409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium and phosphorus in diet therapy of uremia.
    Schoolwerth AC; Engle JE
    J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy.
    Lafage MH; Combe C; Fournier A; Aparicio M
    Kidney Int; 1992 Nov; 42(5):1217-25. PubMed ID: 1453606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
    Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
    Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat.
    Felsenfeld AJ; Machado L; Bover J; Trinidad P; Rodriguez M
    Nephrol Dial Transplant; 1993; 8(4):325-34. PubMed ID: 8390007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sevelamer hydrochloride on bone in experimental uremic rats.
    Kuwahara M; Inoshita S; Terada Y; Sasaki S
    Ther Apher Dial; 2009 Feb; 13(1):42-8. PubMed ID: 19379169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone increases bone formation and improves mineral balance in vitamin D-deficient female rats.
    Toromanoff A; Ammann P; Mosekilde L; Thomsen JS; Riond JL
    Endocrinology; 1997 Jun; 138(6):2449-57. PubMed ID: 9165035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population.
    Andress DL; Maloney NA; Endres DB; Sherrard DJ
    J Bone Miner Res; 1986 Oct; 1(5):391-8. PubMed ID: 3503554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of phosphorus in the genesis of azotemic osteodystrophy.
    Somerville PJ; Kaye M
    Prog Biochem Pharmacol; 1980; 17():228-35. PubMed ID: 6894195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate.
    Canalejo A; Canalejo R; Rodriguez ME; Martinez-Moreno JM; Felsenfeld AJ; Rodríguez M; Almaden Y
    Nephrol Dial Transplant; 2010 Apr; 25(4):1087-97. PubMed ID: 19934096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic bone disease in chronic renal failure. I. Dialyzed uremics.
    Huffer WE; Kuzela D; Popovtzer MM
    Am J Pathol; 1975 Mar; 78(3):365-84. PubMed ID: 1119535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of endothelin receptor antagonist on parathyroid gland growth, PTH values and cell proliferation in azotemic rats.
    Jara A; von Höveling A; Jara X; Burgos ME; Valdivieso A; Mezzano S; Felsenfeld AJ
    Nephrol Dial Transplant; 2006 Apr; 21(4):917-23. PubMed ID: 16431896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid gland function in the uremic rabbit.
    Bas S; Bas A; Estepa JC; Mayer-Valor R; Rodriguez M; Aguilera-Tejero E
    Domest Anim Endocrinol; 2004 Mar; 26(2):99-110. PubMed ID: 14757183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caclium, phosphorus, and bone in renal disease and transplantation.
    Bricker NS; Slatopolsky E; Reiss E; Avioli LV
    Arch Intern Med; 1969 May; 123(5):543-53. PubMed ID: 4888973
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium and phosphorus metabolism and bone disease in uremia.
    Kleeman CR; Massry SG; Coburn JW; Popovtzer MM
    Clin Orthop Relat Res; 1970; 68():210-37. PubMed ID: 4905786
    [No Abstract]   [Full Text] [Related]  

  • 20. Parathyroid function in normocalcemic renal transplant recipients: evaluation by calcium infusion.
    Mitlak BH; Alpert M; Lo C; Delmonico F; Neer RM
    J Clin Endocrinol Metab; 1991 Feb; 72(2):350-5. PubMed ID: 1991804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.